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Purpose: Recent clinical trials have demonstrated that zoledronic acid (ZOL) significantly prolongs survival in prostate cancer 
patients undergoing androgen deprivation therapy. This pilot study investigated the influence of ZOL on circulating tumor cell (CTC) 
counts in prostate cancer patients in association with prostate-specific antigen (PSA) used as a serum biomarker.
Methods: Patients with metastatic castration-resistant prostate cancer (CRPC) who were CTC-positive (n =4) were enrolled in 
treatment with ZOL between April 2012 and December 2013.  CTCs were detected using the Cell Search System. The study evaluated 
CTC fluctuations at 1, 2, and 3 months versus baseline, as well as patient outcomes and adverse events.
Results: Two patients showed evidence of temporally decreased CTCs after ZOL treatment. Instead of decreasing the number of 
CTCs, the PSA level did not go down during the ZOL treatment. One patient could not undergo ZOL treatment due to rapid disease 
progression.
Conclusions: Although CTC count arguably provides useful information about patients undergoing ZOL treatment, the positive 
influence of ZOL may be limited to temporary effects for CRPC.
Keywords: Zoledronic acid, Circulating neoplatic cells, Prostate neoplasms
Prostate Int 2014;2(3):147-151 • http://dx.doi.org/10.12954/PI.14056
Original Article
Corresponding author: Shigeo Horie
Department of Urology, Juntendo University, Graduate School of Medicine, 2-1-1 bunkyo-ku, Hongo, Tokyo 1138421, Japan
E-mail: shorie@juntendo.ac.jp / Tel: +81-3-3813-3111 / Fax: +81-3-5802-1227 
Submitted: 17 June 2014 / Accepted after revision: 21 August 2014
INTRODUCTION
Increasingly malignant cancer cells create an intravascular 
influx as they permeate blood vessels [1]. Several studies have 
confirmed that circulating tumor cells (CTCs) in the blood 
of breast, colorectal, and now prostate, cancer patients are 
a predictive factor of a poor prognosis [2-5]. Recent review 
articles suggest that tumor progression-specific CTCs not 
only identify cancer, but also its activity level [2-5]. Blood 
CTC count is strongly related to the prognosis for patients 
who have undergone therapy for castration-resistant prostate 
cancer (CRPC). CRPC patients, among whom pretreatment 
levels were 5 CTCs/7.5-mL blood, showed a significantly 
higher survival rate than baseline patients whose values were 
5 or more CTCs/7.5-mL blood [6]. These findings suggest that 
CTC count may be a potential marker predicting treatment 
outcome and survivability in CRPC patients. They also clarify 
that patients whose high CTC counts undergo a marked 
decrease may expect an improved survivability, and that pa-
tients whose low CTC counts markedly increase may expect a 
worsening survivability [6]. The implication, therefore, is that 
CTC may act as a useful biomarker for patient condition and 
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venous ZOL administration in 4-week intervals (on days 0, 28, 
and 56) at our hospitals (Teikyo University School of Medicine, 
Sapporo Medical University School of Medicine, and Juntendo 
University, Graduate School of Medicine). Blood was collected 
prior to each ZOL administration for CTC and PSA measure-
ment, with an additional collection during the 4th week 
following the third administration to facilitate weekly safety 
assessments. During the trial, no change was made in tumor 
treatment.
 The following patients were excluded from this study: those 
with a corrected serum calcium level of less than 8.0 mg/dL 
or more than 12.0 mg/dL, those with a history of malignancy, 
and those with (upper or lower) tooth or jaw infection or 
combined dental disease. This study was conducted following 
permission from the Ethics Committee, the informed consent 
of the participants, and screening for ten patients. The four 
patients in whom CTCs were detected agreed to participate, 
and were enrolled in the study.
2. Blood sample collection and CTC analysis
Venous blood was collected at the clinical site into Cell-Save 
Preservative Tubes (Veridex, Raritan, NJ, USA) containing cel-
lular preservatives and ethylenediaminetetraacetic acid as an 
anticoagulant. Blood was collected from patients before and 
after zoledronic acid treatment. In addition, routine laboratory 
analyses were conducted including PSA, lactate dehydroge-
nase, alkaline phosphatase, hemoglobin, and calcium. CTCs 
were isolated and processed from 7.5-mL peripheral venous 
blood using CellSearch System (Veridex, Raritan, NJ, USA) ac-
cording to the manufacturer’s protocol. Two independent well 
operators performed a blind evaluation of the selected cells. 
CTCs were identified by nuclear and cytokeratin staining and 
the absence of the leukocyte typical CD45 epitope.
RESULTS
Ten metastatic CRPC patients who were candidates for this 
study were examined for CTCs; 4 individuals were found to 
have CTCs and were administered ZOL. Patient backgrounds 
are shown in Table 1. 
 Adverse events were evaluated as follows. Case 1: The pa-
tient was found to have grade 1 facial edema and requested 
termination of ZOL. Case 2: The patient experienced rapid 
disease progression, resulting in a change of therapy two 
months following initial ZOL administration. Two of the four 
patients were able to complete the study. Case 3: One patient 
had a CTC count of 3 prior to initial ZOL administration, de-
creasing to 1 two months later. In the third month, however, 
therapy, suggesting continuation of favorable treatment or an 
early alteration of ineffective treatment.
 Zoledronic acid (ZOL) is a bisphosphonate widely recog-
nized as a treatment for bone metastasis and hypercalcemia 
of malignancy. It is also administered to breast and prostate 
cancer patients, along with those suffering from multiple my-
eloma, to prevent skeletal-related events (SRE) following bone 
metastasis [7-12]. Several trials have shown that early-stage 
administration of bisphosphonate preserves bone mass, dem-
onstrating its efficacy against bone loss. A placebo-controlled 
randomized clinical trial showed that SRE incidence de-
creased following ZOL administration in men with metastatic 
prostate cancer who had received hormone refractory therapy 
[9]. ZOL not only elevates bone mineral density (BMD) in 
prostate cancer patients, it also prevents bone loss and has 
demonstrated efficacy against SREs.
 Moreover, bisphosphonate administration has been shown 
to aid survivability of various cancers including bladder and 
prostate cancer patients in multiple prospective randomized 
trials [13-17]. A Myeloma IX study demonstrated that this sur-
vivability was not only due to reduced bone fractures, but also 
reflected a direct ZOL antitumor effect [13]. ZOL facilitates 
inhibition of the chief enzyme in the mevalonate pathway 
(known to stimulate angiogenesis and promote cell survival), 
and is postulated to have a direct effect on tumors. In vitro 
studies have demonstrated that joint use of ZOL and a che-
motherapy agent such as docetaxel or doxorubicin produces 
synergistic antitumor activity. ZOL administration has shown 
to improve overall survivability in breast cancer patients with 
bone metastasis, with data from several recent breast cancer 
adjuvant treatment studies showing ZOL antitumor efficacy 
in early-stage patients [18-20].
 We administered ZOL to cancer patients with bone metas-
tasis three times in 4-week intervals, studying the effects on 
CTCs over a 12-week period. We reasoned that if ZOL could 
be shown to reduce CTCs in CRPC patients with bone metas-
tasis, its direct anti-tumor effect in prostate cancer patients 
might also be demonstrable.
MATERIALS AND METHODS
1. Patients
We conducted a prospective single-arm, open-label study in 
CRPC patients with bone metastasis and no history of bisphos-
phonate treatment. All patients gave written informed consent, 
and approval was obtained from the hospital Research Ethics 
Board. CRPC patients all had confirmed bone metastasis to at 
least one site. Patients followed a treatment protocol of intra-
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predictive factor in CRPC prognosis [28]. CTCs were not de-
tected in patients with relatively low PSA values whose disease 
was progressing slowly. The current findings should serve as 
important information in the design of any future large-scale 
clinical trial.
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36
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CTC, circulating tumor cell; PSA, prostate-specific antigen. 
a)Discontinuance with adverse event. b)Discontinuance with disease 
progression.
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